Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791915 | 0.95 | SLC2A1 (0.63) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL13097087 | 0.94 | SLC2A1 (0.57) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL22406145 | 0.92 | SLC2A1 (0.54) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL13349776 | 0.92 | GPR119 (0.57) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL30876499 | 0.92 | SLC2A1 (0.54) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL864389 | 0.92 | SLC2A1 (0.55) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL29576543 | 0.92 | SLC2A1 (0.55) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL22265848 | 0.92 | SLC2A1 (0.55) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL13160667 | 0.92 | SLC2A1 (0.55) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL7398625 | 0.91 | SLC2A1 (0.53) | SLC2A1KDM4EPKMGPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE CO (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023230541-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | CCR5, THPO, IL5 | SLC2A1 714/4885KDM4E 1863/4885PKM 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.